Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer

Study:

Efficacy and Toxicity of Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer With Progression After Treatment With Docetaxel

Rationale:

n/a

Purpose:

Cabazitaxel is already approved by the Food and Drug Administration (FDA) for use in patients with advanced prostrate cancer, following docetaxel therapy. The purpose of this study is to better understand the response and toxicity of cabazitaxel of elderly men (age 75 years and older) with advanced prostate cancer who have progressed during or after treatment with docetaxel. All patients on this study will receive cabazitaxel by intravenous (through a vein) infusion plus prednisone by mouth twice daily, and following the chemotherapy infusions, an injection of a granulocyte colony-stimulating factor (G-CSF). G-CSF will help the body produce more white blood cells, which should help decrease the risk of getting an infection while being treated with cabazitaxel.

Study Status: Recruiting

Recruiting:
n/a

Condition Intervention Phase
Castrate-resistant Metastatic Prostate Cancer Drug: Cabazitaxel
Drug: Prednisone
Drug: Granulocyte colony-stimulating factor (G-CSF)
Phase 2

Verified by Case Comprehensive Cancer Center July, 2013

Sponsored by: Case Comprehensive Cancer Center
Information provided by: Case Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT01750866

Study Type: Interventional

Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44195
United States

Dale Shepard, Md, PhD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site